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Accepted 17 October 2014; Published online 15 December 2014AbstractObjectives: To assess the quality of reporting and accuracy of a priori estimates used in sample size calculations for cluster randomized
trials (CRTs).
Study Design and Setting: We reviewed 300 CRTs published between 2000 and 2008. The prevalence of reporting sample size ele-
ments from the 2004 CONSORT recommendations was evaluated and a priori estimates compared with those observed in the trial.
Results: Of the 300 trials, 166 (55%) reported a sample size calculation. Only 36 of 166 (22%) reported all recommended descriptive
elements. Elements specific to CRTs were the worst reported: a measure of within-cluster correlation was specified in only 58 of 166 (35%).
Only 18 of 166 articles (11%) reported both a priori and observed within-cluster correlation values. Except in two cases, observed within-
cluster correlation values were either close to or less than a priori values.
Conclusion: Even with the CONSORT extension for cluster randomization, the reporting of sample size elements specific to these trials
remains below that necessary for transparent reporting. Journal editors and peer reviewers should implement stricter requirements for au-
thors to follow CONSORT recommendations. Authors should report observed and a priori within-cluster correlation values to enable com-
parisons between these over a wider range of trials.  2015 The Authors. Published by Elsevier Inc. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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In a cluster randomized trial (CRT), groups or ‘‘clusters,’’
rather than the constituent individuals themselves, are
randomly allocated to interventions [1,2]. A cluster could
be, for example a medical practice, hospital, or community.
Cluster randomization may be deemed necessary when
randomization at individual level is impractical, for example,Conflict of interest: None.
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licenses/by-nc-nd/3.0/).when the intervention is necessarily administered at the clus-
ter level. There can also be scientific reasons to adopt cluster
randomization, for example to avoid contamination between
treatment groups or for reasons of administrative conve-
nience or cost. In aCRT, the responses from different individ-
uals within the same cluster are usually more similar than
those from different clusters. The degree of this correlation
is commonly quantified by the intracluster correlation coeffi-
cient (ICC) but can also be quantified using the coefficient of
variation of the outcome, often referred to as k [3]. Sample
size calculations for CRTsmust take correlation into account
to avoid potentially underestimating the required sample
size. Donner et al. [4] proposed that a sample size calculated
assuming individual randomization can be inflated by a
design effect (DE) to reach the required level of statistical
power under cluster randomization. This DE is.ess article under the CC BY-NC-ND license (http://creativecommons.org/
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 This is the first article to evaluate sample size re-
porting prevalence for each of the CONSORT
2004 recommended sample size descriptive ele-
ments for cluster randomized trials (CRTs).
 There is much room for improvement in sample
size reporting. Sample size elements specific to
CRTs were the worst reported.
 Comparisons between a small sample of a priori
estimates and observed values of the within-
cluster correlation show the a priori estimates to
be reasonably accurate.
 There seems to be a discrepancy between endorse-
ment of CONSORT by journals and implementa-
tion by authors.
 We recommend journals to consider making adher-
ence to CONSORT guidelines and extension state-
ments a condition of publication.DE51þ ðn 1Þr
where n is the number of individuals per cluster and r the
ICC. For example, using this formula, a trial with 35 indi-
viduals per cluster and an anticipated ICC of 0.01 would
require 34% more participants than the equivalent individ-
ually randomized design. When cluster sizes are unequal, n
is usually replaced by the average cluster size, although this
risks potentially underestimating the required sample size
[5]. Since 2001, various methods for accounting for vari-
able cluster size have been published [5e10].
Reporting how the sample size calculation was per-
formed is important from both a scientific and ethical
perspective to show that the trial was designed to
adequately address the research question without wasting
resources or exposing too many participants to potentially
harmful interventions. The CONSORT statement recom-
mends the reporting of 25 items related to the design,
conduct, and analysis of randomized controlled trials. The
statement was first published in 1996 [11] and revised in
2001 [12] and 2010 [13]. This latest revision is referred
to as CONSORT 2010. The CONSORT statement was
developed with the dual aims of standardizing reporting
and facilitating transparency. The transparent reporting of
sample size methods and assumptions provides some reas-
surance to the reader of the quality with which the trial has
been conducted. Ideally, adequate reporting ensures that a
reader can appraise the methodology; identify whether an
appropriate and a priori calculation was performed for the
study design; and assess whether the assumptions made
in the sample size calculation were reasonable.The item that relates to describing the sample size calcu-
lation in CONSORT 2010 recommends the following
descriptive elements to be reported (1) the estimated out-
comes in each group (which implies the minimum important
treatment effect), (2) the level of significance [or thea (type I)
error level], (3) the statistical power [or the b (type II) error
level], and (4) for continuous outcomes, the assumed stan-
dard deviation of the measurements. The CONSORT state-
ment was extended in 2004 [14] for the reporting of CRTs,
and this was revised in 2012 [15] to be in line with CON-
SORT 2010. This extension includes adaptations to items
relevant to the reporting of CRTs. The item that relates
to describing the sample size calculation additionally recom-
mends the reporting of two further descriptive elements (5)
the number of clusters or the cluster size and (6) the ICC or
coefficient of variation (k), along with a measure of its uncer-
tainty. The 2012 revision additionally recommends specifica-
tion of whether equal or unequal cluster sizes are assumed.
Adherence to all the reporting items provided in the
2004 CONSORT extension for CRTs has been reviewed
in 23 trials in oral health [16], 300 randomly sampled trials
[17], 106 trials in children [18], and 73 trials in residential
facilities [19]. The presence of a sample size calculation in
a trial report is considered an initial indication of reporting
quality in the area of sample size. Across these reviews, the
proportion presenting a calculation was 21 of 23 (91%),
164 of 300 (55%), 87 of 106 (82%), and 43 of 73 (59%),
respectively. The third review also reports that 63 of 87
(72%) of trials reported all 2004 CONSORT recommended
sample size descriptive elements. Unlike our review, none
of these reviews identify which of the six sample size
descriptive elements are reported and which are not.
To ensure methodological quality, a sample size calcula-
tion should be appropriate to the trial design. For a CRT,
this implies a sample size calculation accounting for clus-
tering, either by correctly accounting for the clustered na-
ture of the data using a suitable estimate of within-cluster
correlation or calculating the sample size from cluster-
level measures. A cluster-level sample size provides the
number of clusters required and may be undertaken when
information on cluster size is unavailable at the design
stage and/or the primary outcome itself takes some account
of cluster size [20]. Many reviews of the methodological
conduct of CRTs show that this methodological aspect is
suboptimal: for example, in two reviews mentioned above,
100 of 164 (61%) and 15 of 21 (71%) trials that reported a
sample size calculation also accounted for the clustered na-
ture of the design [16,17].
In addition to using an appropriate methodology, it is
vital that a sample size calculation is realistic and that, in
principle, the required numbers can be recruited. Ideally,
sample size calculations should use a within-cluster corre-
lation based on the best available data and specify a mini-
mum treatment effect that is both clinically important and
is likely to be achievable based on evidence from previous
trials of similar interventions. However, it is recognized
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may not be available or circumstances outside the investi-
gators’ control may make the same size unobtainable. A
comparison between the estimates used in the sample size
calculations and those observed at the end of the trial in a
sample of individually randomized trials concluded that
sample size calculations are often based on inaccurate as-
sumptions [21]. We are unaware of any previous studies
considering similar discrepancies for CRTs.
The review by Ivers et al. [17] found that the prevalence
of reporting sample size calculations was low and that cal-
culations were not always appropriate for the clustered na-
ture of the trial. In this review, we use the same sample of
trials to look in more detail at sample size calculations in
these trials, assessing adherence to reporting descriptive
sample size elements in the 2004 CONSORT extension.
In particular, we aim to identify which elements are under-
reported, whether reporting has improved since the intro-
duction of the 2004 CONSORT extension, and the
accuracy of the a priori estimates used in the sample size
calculation by making comparisons with their observed
values at the end of the trial.2. Materials and methods
2.1. Search strategy
We used a previously published review of 300 reports of
CRTs randomly sampled from MEDLINE. The search
strategy and characteristics of the included studies have
been described in detail elsewhere [17]. Briefly, a publica-
tion was included if it was published in an English language
journal between the years 2000 and 2008, and it was the
main report of a CRT; trial protocols, pilot studies, second-
ary analyses of CRTs, and trials with households or families
as clusters, with multistage designs, or presenting only
baseline findings were excluded.
2.2. Data abstraction
We reviewed the sample to identify those that reported
prospective sample size calculations. Data abstraction was
conducted only on these trials. All abstraction relates to
the outcome used in the sample size calculation. This was
the primary outcome in all but 30 trials.
Descriptive information for each journal included year
of publication, impact factor, and whether the journal
endorsed the CONSORT statement (taken from the CON-
SORT Web site [22]). As timing and strength of endorse-
ment are difficult to define, this variable was provided as
a rough indicator of journal quality only and no formal
comparisons of its impact were made. Descriptive informa-
tion for each trial included trial design, method of random-
ization, health area, data type of the sample size outcome,
and whether a statistically significant result was seen for
the sample size outcome (as reported by authors).For the primary objective of reporting quality, abstracted
information for each trial included the values of the 2004
CONSORT required sample size elements and additionally
whether adjustments had beenmade for variable cluster sizes
or attrition. For the secondary objective of methodological
quality and accuracy, abstracted information included
whether the sample size accounted for clustering, including
anymethodology cited, any justifications provided for the es-
timates of the within-cluster variation and estimates of out-
comes in the control and treatment groups, and the
corresponding observed values of treatment effect and
within-cluster correlation at the end of the trial. No assess-
ment was made of whether the correct formulae had been
referenced or implemented given the particular trial design
or whether the sample size calculation could be reproduced.
The research team developed and piloted a data abstrac-
tion instrument and corresponding Access database for
electronic data storage. Three experienced statisticians
(C.R., M.T., and S.D.) abstracted the data for all the articles
in rotating pairs. After each set of 10 trials had been
abstracted, discrepancies were reviewed within the pair
and resolved by discussion.
2.3. Data analysis
2.3.1. Description of sample
Characteristics of the journals and trials for articles con-
taining sample size calculations are summarized using fre-
quencies and percentages or medians and interquartile
ranges.
2.3.2. Reporting according to CONSORT guidelines
For each trial, we describe the 2004 CONSORT required
elements that were provided for the sample size calculation,
with a maximum of six elements. The required elements
were (1) the type I error rate, (2) power, (3) estimates of
outcomes in each group or minimum important target ef-
fect, (4) the standard deviation for continuous outcomes,
(5) the number of clusters or average cluster size, and (6)
the assumed measure of intracluster correlation, design ef-
fect, or coefficient of variation. Trials that do not have a
continuous sample size outcome would not be expected
to provide a standard deviation, and similarly, trials for
which a cluster-level analysis has been assumed in the sam-
ple size calculation are not required to provide a value of
within-cluster correlation. For each trial, we calculate the
maximum number of possible 2004 CONSORT elements
that could have been reported (given the type of outcome)
and the proportion that were reported. For completeness,
we summarize the number of articles that make adjustments
for attrition and variable cluster sizes, although we expect
the latter to be low given that most publications on the sub-
ject were written after the sample sizes would have been
decided for most of our trials, and the specific 2012 CON-
SORT recommendation for reporting this was introduced
after our sample was collected.
Table 1. Journal and trial characteristics of 166 cluster randomized
trials reporting sample size calculations
Characteristic N (%)
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for those articles published before (2000e2004) and after
(2005e2008) its publication.Journal: year of publication
2000e2004 77 (46)
2005e2008 89 (54)
Journal: impact factor, median (IQR) 3.6 (2.3e12.1)
Journal: endorsement of CONSORT 99 (60)
Trial: design
Parallel group 155 (93)
Factorial 5 (3)
Crossover 4 (2)
Stepped wedge 1 (1)
Balanced incomplete block design 1 (1)
Cross sectionala 56 (34)
Cohorta 110 (66)
Trial: method of random allocation:
Completely randomized 61 (37)
Stratified 64 (39)
Within matched sets 31 (19)
Minimization 9 (5)2.3.3. Assessment of methodological approach
The sample size methodology and justifications for the
values of a priori estimates are summarized using fre-
quencies and percentages. A scatter plot of a priori esti-
mates and observed values of within-cluster correlations
is presented.
Where possible, discrepancies are calculated between
the minimum important target effect and the observed
effect as (observed effect/minimum important target effect).
The calculation is performed on the scale the authors used
to report the effect, that is, absolute or relative differences,
odds ratio, or hazard ratio. When the observed effect is
smaller than the a priori minimum important target effect,
this value is !1 regardless of measurement scale.Other 1 (1)
Trial: health area
Primary or hospital care 116 (70)
Public health 50 (30)
Trial: type of primary outcome
Dichotomous 80 (48)
Continuous 56 (34)
Rate 16 (10)
Ordinal 1 (1)
Categorical 0 (0)
Count 0 (0)
Time to event 0 (0)
Unclear 13 (8)
Abbreviation: IQR, interquartile range.
a In a cohort design, repeated measurements are taken on the
same individuals at each time point, and in a cross-sectional design,
repeated measurements take place on different individuals.3. Results
Of the 300 articles, 166 trials (55%) reported a priori
sample size calculations and are thus summarized. (This
number differs from the 164 reported in the original review,
which focused on sample size calculation for a particular
variable identified by reviewers as primary.) The vast ma-
jority [155 of 166 (93%)] were parallel group trials, imple-
menting simple or stratified randomization [125 of 166
(75%)], and used binary or continuous primary outcomes
[136 of 166 (82%)] (Table 1).
The median impact factor of included journals was fairly
low (3.6, interquartile range: 2.3e12.1); however, 99 of 166
(60%) of these were journals whose guidance recommends
use of CONSORT. Nearly half (46%) were published in the
years preceding the first publication of the CONSORT
extension for CRTs.3.1. Reporting according to CONSORT guidelines
Of the CONSORT required elements for sample size
calculation, the most commonly reported were outcome
levels in each group or minimum important target effect
(160 of 166, 96%), power (155 of 166, 93%), and type I er-
ror rate (133 of 166, 80%), Table 2. The elements specific
to CRTs were reported less frequently: number of clusters
or cluster size [94 of 166 (57%)] and a measure of
within-cluster correlation [58 of 166 (35%)].
No articles reported corresponding measures of uncer-
tainty alongside the correlation estimates, although some
[18 of 102 (18%)] assessed sample size sensitivity based
on a range of within-cluster correlation values (Table 3).
The assumed standard deviation was reported in only 18
(32%) of the 56 articles with a continuous outcome. Only
38 (23%) of 166 trials reported explicitly accounting forattrition, and only one article accounted for variable cluster
sizes (Table 2).
Only 36 of 166 articles (22%) reported all the 2004
CONSORT required elements. There was some improve-
ment in reporting over time with 23 of 89 trials (26%) re-
porting all the CONSORT required elements after the
introduction of the extension, compared with only 13 of
77 (8%) before the 2004 CONSORT extension (Table 2).
In particular, improvements were observed with respect to
the standard deviation for continuous outcomes and the re-
ported value of the within-cluster correlation. Categoriza-
tion of journals as above or below the median impact
factor indicated that articles in higher impact journals
tended to report more CONSORT elements: in lower
impact journals, 13 of 83 (16%) reported all required ele-
ments compared with 23 of 83 (28%) in higher impact
journals.
3.2. Assessment of methodological approach
Of the 166 articles reporting a sample size calculation,
102 of 166 (61%) clearly accounted for the within-cluster
Table 2. Reporting of recommended 2004 CONSORT sample size descriptive elements in 166 cluster randomized trials by year of publication
Sample size element
Yr of publication
All yr, N [ 166 (%) 2000e2004, N [ 77 (%) 2005e2008, N [ 89 (%)
(1) Type I error rate (%)
2.5 1 (1)
5 131 (79)
20 1 (1)
Stated 133 (80) 62 (81) 71 (80)
Unclear or not stated 33 (20) 15 (19) 18 (20)
(2) Power (%)
80 115 (69)
85 5 (3)
90 34 (20)
95 1 (1)
Stated 155 (93) 70 (91) 85 (96)
Unclear or not stated 11 (7) 7 (9) 4 (4)
(3) Treatment effect
Outcomes in each treatment group 98 (59)
Minimum important target effect size only 62 (37)
Provided 160 (96) 72 (94) 88 (99)
Not provided 6 (4) 5 (6) 1 (1)
(4) Standard deviationa 18/56 (32) 8/29 (28) 10/27 (37)
(5) Number of clusters or average cluster size 94 (57) 44 (57) 50 (56)
(6) Reported value of ICC, design effect, or coefficient
of variationb
58/93 (62) 26/45 (58) 32/48 (67)
Accounted for attrition 38 (23) 15 (19) 23 (26)
Accounted for variable cluster sizes 1 (1) 1 (1) 0 (0)
Percentage of CONSORT elements reportedc
0 1 (0.6) 1 (1) 0 (0)
1e20 5 (3) 4 (5) 1 (1)
21e40 13 (8) 5 (6) 8 (9)
41e60 54 (33) 21 (27) 33 (37)
61e80 46 (28) 26 (34) 20 (22)
81e99 11 (7) 7 (4) 4 (4)
100 36 (22) 13 (8) 23 (26)
Abbreviation: ICC, intracluster correlation coefficient.
a Standard deviation reported among the 56 trials with a continuous primary outcome.
b Excludes nine trials where the sample size was calculated at the cluster level and hence a measure of correlation is not expected.
c Denominators are 4, 5, or 6 depending on whether values of the standard deviation and correlation are expected given each trial design.
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clustering was accounted for, almost three-quarters speci-
fied the ICC as a measure of the correlation [66 of 102
(65%)], others quoted a DE [11 of 102 (11%)] or coefficient
of variation [9 of 102 (9%)]. Only 52 of 166 (31%) cited a
methodology for the calculation.
No justification was provided for the estimate of the
postulated outcome in the control group in 113 of 166 trials
(68%), for the estimated treatment outcome or minimum
important target effect in 127 of 166 (77%), and for the cor-
relation estimate in 52 of 102 (51%). Where justified, the
estimated outcome for the control group was most often
estimated from previous trials, the minimum important
target effect justified by clinical relevance, and the
within-cluster correlation chosen from a plausible range.
Only 18 trials reported a measure of the within-cluster
correlation both a priori and at the end of the trial. With
the exception of two trials, the a priori estimate was close
or slightly larger than the observed estimate. The largest
differences were seen in the smaller trials (Fig. 1).Comparison of the minimum important target effect and
observed effect was possible for 136 trials (82%). Thirty
trials were excluded from this comparison: 13 due to lack
of reporting a treatment effect, either a priori or observed,
and 17 where it was not possible to abstract comparable
measures of treatment effect at both time points. In most
trials [93 of 136 (68%)], the observed treatment effect
was less than the a priori value used in the sample size
calculation. The median relative reduction was 74% (inter-
quartile range: 25e111%).4. Discussion
Reporting guidelines such as the CONSORT statement
were developed to aid standardized and transparent report-
ing and to provide the reader with enough information to
critically appraise the design, conduct, and analysis of the
research. It is important to be able to identify whether an
appropriate sample size calculation was performed and
whether the assumptions can be considered reasonable.
Table 3. Sample size approach and justification for values of a priori
estimates for 166 cluster randomized trials
Sample size method N [ 166 (%)
(1) Sample size accounted for clustering 102/166 (61)
Intracluster correlation 66/102 (65)
Design effect 11/102 (11)
Coefficient of variation 9/102 (9)
Unclear or not stated 7/102 (7)
Cluster-level calculation 9/102 (9)
Did not account for clustering 48/166 (29)
Unclear 16/166 (10)
(2) Methodology cited 52/166 (31)
(3) Justification of a priori estimates
(3a) The control group expected outcomes, N 5 166
No justification 113/166 (68)
Results from published data 39/166 (23)
A preliminary/pilot study 6/166 (4)
Conservative estimate 8/166 (5)
(3b) The treatment group expected outcome N 5 166
No justification 127/166 (77)
Results from published data 16/166 (10)
A preliminary/pilot study 3/166 (2)
Clinical relevance (no data referenced) 20/166 (12)
(3c) The within-cluster correlation estimate N 5 102
No justification 52/102 (51)
Results from published data 17/102 (17)
A preliminary/pilot study 6/102 (6)
Plausible range 18/102 (18)
NA due to cluster-level calculation 9/102 (9)
Abbreviation: NA, not applicable.
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recommendations of the 2004 CONSORT extension was
poor, with elements specific to cluster randomized designs
being the worst reportedda phenomenon seen in many re-
views assessing the wider aspects of the 2004 CONSORT
extension recommendations, for example [15]. Twenty-
two percent of trials were compliant with all the 2004
CONSORT extension sample size element recommenda-
tions. This is comparable to results seen for individuallyFig. 1. A comparison of a priori and observed estimates of the within-
cluster correlation.randomized trials: In a review of 215 individually random-
ized trials published in 2005 and 2006 in six high-impact
medical journals, 34% of trials included enough informa-
tion for full replication of the sample size [21]. However,
we are encouraged to see in our review some improvements
over time in the number of trials reporting all the required
CONSORT sample size elements with increases occurring
in the reporting of the within-cluster correlation. This is
particularly important given the large influence that this
parameter has on the required sample size.
Our sample contained only trials published until 2008.
This allowed us to assess the immediate impact of the
CONSORT extension statement in the 4 years after its pub-
lication. This review provides an important baseline with
which to compare the impact of future CONSORT state-
ments. We plan to repeat this review, including more recent
articles, to assess the immediate effects of the 2012 revision
once there has been sufficient time for it to take full effect
and a large number of trials published. A secondary aim of
a future review will be to look at the medium- to long-term
impact of the 2004 CONSORT extension.
We acknowledge the limitation that the current review
does not allow us to assess the medium- to long-term
impact of the 2004 CONSORT extension. However, this
sample is unique in both its size and its coverage of all
medical areas and journals; hence, it provides us with an
important insight into the immediate uptake of the CON-
SORT extension among the medical researcher field in
general. Most of the other reviews of CRTs have contained
less than 40 trials, with the largest containing 173
[16,19,23e33]. This sample of 300 is the largest to date,
with the largest sample of identified sample size calcula-
tions. Previous reviews have also focused on particular
areas of health such as stroke, oral health, or primary care
or targeted particular high ranking journals during the
search. Our sample was designed to be representative of
CRTs across the health research field.
Additional adjustments for attrition and variable cluster
sizes were made in only 38 (23%) and 1 (1%) of trials,
respectively. We expected the latter figure to be low as rele-
vant publications describing how to do this are relatively
recent and the recommendation to report information on
cluster size variability has only recently been included in
CONSORT. Failure to take into account these additional
considerations may lead to an underestimate of the sample
size required, the effect of variable cluster size only being
negligible when the coefficient of variation in cluster size
is small (less than 0.23) [5]. Simple DE approaches to deal
with variable cluster sizes are available [5e8].
Sixty percent of the articles included in our review were
in journals whose recommendations mention CONSORT.
Although we recognize that it is not known at what time
each journal first endorsed CONSORT or whether the
extension statements are similarly endorsed, there does
seem to be a discrepancy between endorsement and use
of CONSORT. The way in which medical journals
722 C. Rutterford et al. / Journal of Clinical Epidemiology 68 (2015) 716e723incorporate CONSORT recommendations into their edito-
rial process has been surveyed [34]. That survey found that
38% (62 of 165) and 3% (5 of 165) of journals recommend
that authors comply with CONSORT and the cluster exten-
sion, respectively, within their instructions to authors, but
only 37% (23 of 62) and 60% (3 of 5) make it a require-
ment. These figures are higher when surveying journal ed-
itors directly, with 69% (31 of 45) recommending that
authors comply with the extension for CRTs. However,
we recognize that endorsement of CONSORT by journals
may not be the sole driver behind improving reporting qual-
ity. A recent review of reporting quality in CRTs concluded
that quality of reporting and conduct was influenced more
by the presence of a statistician (or quantitative researcher)
among the authorship than a journal’s endorsement of
CONSORT [19].
From the original sample of 300 trials, only 166 (55%)
presented an a priori sample size calculation. Where a sam-
ple size calculation was reported, clustering was accounted
for in 102 of 166 (61%) of these trials. This figure is quite
poor given the standard trial design adopted by many of the
included studies, for which there are simple sample size
methodologies available. A limitation of our study is that
we did not assess whether each trial was appropriately pow-
ered. We did not reproduce sample size calculations or
assess the assumptions made about cluster size, as a mea-
sure of observed cluster size variability was not collected
and recommendations for reporting this have only been
made recently.
In our sample, only a small number of trials reported
both the a priori and observed correlation estimates. This
was similarly seen in a review of CRTs in cancer screening
where only 7 of 50 (14%) reported both a priori estimated
and observed ICCs, and there was no evidence that its re-
porting improved after the CONSORT statement extension
[35]. Given its influence, it is important for authors to pro-
vide the observed valuednot only to aid the design of
future trials, but also to allow one to assess the accuracy
of the a priori estimates and hence the sample size. Albeit
on a small and possibly unrepresentative sample, compari-
sons between a priori estimates and observed values of the
within-cluster correlation showed that authors tended to as-
sume conservative estimates. Part of the explanation for this
may be that values of ICCs used in sample size calculations
are usually not adjusted for covariates, whereas observed
ICCs may be adjusted for covariates (and hence smaller).
Furthermore, our results are consistent with part of any
discrepancy between observed and assumed ICCs being
due to sampling error; the discrepancy was generally larger
in small trials. Whether our findings remain in a larger,
more representative, sample remains to be seen. The a pri-
ori estimate of the within-cluster correlation may be taken
from a previous trial or alternatively, if using the ICC, there
are published summaries available for ICCs of specific out-
comes [36e39]. In our sample, few authors provided an
explanation for their assumed estimate.The observed treatment effect was often smaller than the
minimum important target effect used in the sample size
calculation. This could be because interventions are often
ineffective or because in some cases investigators power tri-
als using minimum important target effects that could never
be achieved with the type of intervention under evaluation.
Careful consideration is required in determining the mini-
mally important effect in trials of complex interventions,
both in individually randomized and CRTs [1].
The results from our review show that there is much
room for improvement in the conduct and reporting of sam-
ple size calculations in CRTs. We recommend that journals
consider making adherence to CONSORT guidelines a con-
dition of publication to aid improvement in the quality of
reporting and methodological conduct of CRTs.References
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